Uncategorized
Biogen says Leqembi sales are improving slowly following lackluster launch
Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)
Moderna expands effort to rein in costs in an uncertain environment
Moderna, Financial cost, Uncertainty, Environment
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
Novartis bolsters renal disease pipeline with $1.7B deal for Regulus
Goldcrest, farabursen, Novartis
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis
Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction
Entrada tightens focus on Duchenne, axes 20% of staff
Duchenne muscular dystrophy (DMD), workforce reduction, ENTR-601-44, ENTR-601-45, FDA clinical hold, exon skipping therapy
Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments
False Claims Act, Medicare fraud, average sales price inflation, credit card fees, price concessions, DOJ lawsuit
Novartis to buy Regulus Therapeutics for up to $1.7B
Goldcrest, Novartis, Acquisition (action), Kidney Diseases
AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap
Truqap, AstraZeneca, Television, Faslodex, Malignant neoplasm of breast